Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.60 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinimide SCHEMBL2208960 | 0.85 | MMP1 (0.47) | DDB1CRBNNPC1RAB9AKMT2A | |
| SCHEMBL30001820 | 0.83 | ALDH1A1 (0.68) | ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL78553 | 0.83 | ALDH1A1 (0.68) | ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2 | |
| Succinimide SCHEMBL2210256 | 0.82 | MMP12 (0.50) | DDB1CRBNKMT2AMAOBMMP1 | |
| Bicarbonate SCHEMBL29183462 | 0.81 | ALDH1A1 (0.65) | ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2 | |
| Hydrogen Sulfide SCHEMBL2021838 | 0.81 | ALDH1A1 (0.65) | ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL3839713 | 0.81 | ALDH1A1 (0.65) | ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28226984 | 0.81 | ALDH1A1 (0.65) | ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2 | |
| Water SCHEMBL8217832 | 0.81 | ALDH1A1 (0.65) | ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11630242 | 0.81 | ALDH1A1 (0.65) | ALDH1A1MAPK1SMN1; SMN2TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113227045-B | Synthesis of substituted heterocycle fused gamma-carbolines | 细胞内治疗公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-113195450-B | Synthesis of substituted heterocycle fused gamma-carbolines | 细胞内治疗公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-109715612-A | SOMATOSTATIN MODULATORS AND USES THEREOF | 克林提克斯医药股份有限公司 | 2019-05-03 | — | — | CN | disclosed |
| US-7982045-B2 | 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| US-20090192096-A1 | 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-07-30 | — | — | US | disclosed |
| US-7514582-B2 | 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20040102513-A1 | 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2004-05-27 | — | — | US | disclosed |
| US-6686395-B2 | THERAPY OF A CARDIAC ARRYTHMIA WHICH CAN BE ELIMINATED BY ACTION POTENTIAL PROLONGATION; POTASSIUM CHANNEL MODULATOR | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-03 | — | — | US | disclosed |
| US-20030171351-A1 | 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-09-11 | — | — | US | disclosed |
| US-6531495-B1 | Potassium channel | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171351-A1 | 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | MLLT3, RYR2, KCNH1 | DDB1 3131/4885CRBN 1997/4885ALDH1A1 217/4885 |
| US-20090192096-A1 | 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them | MLLT3, RYR2, CACNA1E | DDB1 2988/4885CRBN 1991/4885ALDH1A1 269/4885 |
| US-20040102513-A1 | 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | MLLT3, RYR2, CACNA1E | DDB1 2951/4885CRBN 2054/4885ALDH1A1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.